GLP-1 medicines are prescription treatments with much larger, more consistent effects on both, backed by very large trials
This aligns with findings from SURPASS-CVOT, which showed no meaningful additive effect on MACE compared to an older GLP-1 receptor agonist, and with findings of a potential greater protection in heart failure that could be compatible with more pronounced weight loss mediated by GIP 16,22
Ro offers access to all four of these weight loss medications for eligible patients
The difference in weight loss is significant
The pathophysiology is still unclear, with the involvement of brain iron deficiency, dysfunction in the dopaminergic and nociceptive systems and altered adenosine and glutamatergic pathways as hypotheses being investigated
Overall, as GLP-1RAs become increasingly prescribed, further pharmacovigilance studies are warranted, noted the authors